Study S001071

A Phase 1, Randomized, Open-label, Single-dose, Parallel Group Study to Assess the Relative Bioavailability of AMG 133 Administered Using One of Three Drug Products in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07717814
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 154
Start: 2024-11-26
Primary completion: 2025-05-22
Lead sponsor: Amgen
Conditions: Overweight and Obesity
Interventions: DRUG:AMG 133 (frozen liquid); DRUG:AMG 133 (liquid)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Maximum Observed Concentration (Cmax) of AMG 133 [Up to Day 120]
Area Under the Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120]
AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133 [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.